Blood Loss, Surgical
Conditions
Keywords
Viscoelastic testing, Coagulation, Quantra, Hemostasis
Brief summary
This study will monitor coagulation parameters during the perioperative course of cancer surgical procedures using the Quantra System with the QPlus Cartridge.
Detailed description
The Quantra System is a fully integrated and automated in vitro diagnostic device which uses SEER Sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. The Quantra QPlus Cartridge was developed to monitor hemostasis during major surgical procedures in adult patients. The cartridge consists of four independent channels each containing different sets of reagents, which provide four measurements performed iin parallel yielding six parameters that depict the functional status of a patient's coagulation system. The oncologic surgical population presents unique challenges to providers who must distinguish between a cancer patient's increased tendency toward both thrombosis and hemorrhage. This single site prospective observational study in oncologic patients will give an insight into the coagulation status of critically ill cancer patients.
Interventions
DIAGNOSTIC_TESTQuantra System
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Sponsors
HemoSonics LLC
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject is \>= 18 years * Subject is diagnosed with cancer and is scheduled for surgical resection * Subject is willing to participate, and he/she or a Legally Authorized Representative (LAR) has signed a consent form * Surgical procedure to be performed has an anticipated blood loss (\>500mL) based on historical data
Exclusion criteria
* Subject is younger than 18 years * Subject or a subject's LAR is unable to provide written informed consent * Subject is undergoing an emergent procedure. * Subject is pregnant, has active liver disease, or severe renal dysfunction (creatinine clearance (CrCL)\<30 mL/min) * Subject has an extremely low platelet count (\<40,000/uL) * Subject is currently enrolled in a distinct study that might confound the results of the proposed study * Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Quantra Clot Time results to TEG R results | Baseline, defined as after induction of anesthesia, before surgical incision | Coagulation function assessed by Quantra and TEG 5000 |
| Comparison of Quantra Clot Stiffness results to TEG MA results | Baseline, defined as after induction of anesthesia, before surgical incision | Coagulation function assessed by Quantra and TEG 5000 |
| Comparison of Quantra Time results to TEG R results | During surgery | Coagulation function assessed by Quantra and TEG 5000 |
Countries
United States
Outcome results
None listed